Pegcetacoplan Maintains Kidney Benefits at 52 Weeks

Pegcetacoplan, a targeted C3/C3b inhibitor, shows sustained, robust effects on key markers of kidney disease in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to 52-week results from the VALIANT trial.  The 26-week results, which were presented last October at Kidney Week 2024…